Northwire Canada EditionThursday, October 15, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4% GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4%
M&A / Property Routine +

Crescita Therapeutics Inc. Announces Final Consideration Payable to Shareholders Pursuant to Arrangement with ClinActiv

Crescita Therapeutics Inc.

By The Northwire Desk — AI Analysis Jun 01, 2026 · 20:59 CTX · 0.75 CRESCITA THERAPEUTICS INC. J
Executive Summary
  • Crescita Therapeutics announced the final consideration payable to shareholders for its acquisition by ClinActiv Holdings Inc.
  • The transaction is an all-cash deal valued at $0.80 per share, subject to net working capital adjustments.
  • Closing is expected on June 3, 2026, pending standard conditions.
  • Upon closing, shares will be delisted from the TSX and the company will apply to cease reporting status under Canadian securities laws.
  • This follows overwhelming shareholder approval (99.58% in favor on May 14) and final court approval from the Ontario Superior Court of Justice (May 20).
Material Impact
  • The June 1 announcement is a procedural final step in a transaction originally announced on March 16, 2026.
  • The stock has traded in a tight $0.74–$0.76 range since the deal announcement, fully pricing in the $0.80 offer.
  • The announcement confirms imminent closure and provides a clear liquidity event for shareholders.
  • From a risk-averse perspective, the arbitrage spread is minimal (~$0.04–$0.06). The primary risk is deal termination, though the $2M CAD / $1.5M USD termination fees provide a downside floor.
  • No new fundamental catalysts are introduced; the market impact is neutral to slightly positive as it removes execution uncertainty and confirms the timeline.
CTX · Price
Company Overview
  • Crescita Therapeutics is a biotechnology and skincare company focused on commercial skincare products and contract manufacturing services.
  • Flagship assets include the Bacti Control® brand (acquired from Laboratoire Provence-Canada) and a contract manufacturing facility.
  • Q1 2026 revenue reached $5.6M (+59% YoY), driven by manufacturing volumes and skincare growth.
  • Gross margin improved to 46.9%. The company renewed its manufacturing lease through September 2031.
  • The pending acquisition will transfer the commercial skincare and manufacturing business to ClinActiv, while senior management retains remaining assets.
Read the original news release →

More from CRESCITA THERAPEUTICS INC. J

Jun 03, 2026 · 18:07

Crescita Therapeutics Closes $0.80 All-Cash Acquisition by ClinActiv, Delisting TSX and Cashing Out Shareholders

M&A / Property May 20, 2026 · 17:07

Crescita Therapeutics Secures Final Court Approval for ClinActiv Acquisition; Shares Trade Near Offer Price

M&A / Property May 14, 2026 · 13:48

Crescita shareholders overwhelmingly back ClinActiv buyout, paving the way for a clean exit at the premium offer.

M&A / Property May 11, 2026 · 07:30

Crescita Shares Trade Near Buyout Price as Q1 EBITDA Turnaround Validates Deal Viability

Earnings Apr 22, 2026 · 19:13

Crescita Therapeutics Moves Closer to ClinActiv Takeover at $0.80 Premium

M&A / Property Mar 31, 2026 · 07:30

Crescita Locks $0.80 Buyout as Q4 Earnings Validate Manufacturing Pivot

Earnings